Acetylcholinesterase Inhibitors: Beneficial Effects on Comorbidities in Patients With Alzheimer’s Disease

Vinod Kaushik, Sarah Toombs Smith, Emmanuel Mikobi, Mukaila Raji

Research output: Contribution to journalReview article

  • 1 Citations

Abstract

Elderly patients with Alzheimer’s disease (AD) and other dementias are at high risk of polypharmacy and excessive polypharmacy for common coexisting medical conditions. Polypharmacy increases the risk of drug–drug and drug–disease interactions in these patients who may not be able to communicate early symptoms of adverse drug events. Three acetylcholinesterase inhibitors (ACHEIs) have been approved for AD: donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne). They are also used off-label for other causes of dementia such as Lewy body and vascular dementia. We here report evidence from the literature that ACHEI treatment, prescribed for cognitive impairment, can reduce the load of medications in patients with AD by also addressing cardiovascular, gastrointestinal, and other comorbidities. Using one drug to address multiple symptoms can reduce costs and improve medication compliance.

LanguageEnglish (US)
Pages73-85
Number of pages13
JournalAmerican Journal of Alzheimer's Disease and other Dementias
Volume33
Issue number2
DOIs
StatePublished - Mar 1 2018

Fingerprint

Rivastigmine
Polypharmacy
Cholinesterase Inhibitors
Galantamine
Comorbidity
Alzheimer Disease
Dementia
Pharmaceutical Preparations
Lewy Body Disease
Vascular Dementia
Medication Adherence
Drug-Related Side Effects and Adverse Reactions
Drug Interactions
Costs and Cost Analysis
donepezil
Therapeutics

Keywords

  • acetylcholinesterase inhibitors
  • Alzheimer’s disease
  • comorbidities
  • off-label use
  • polypharmacy

ASJC Scopus subject areas

  • Clinical Psychology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Cite this

Acetylcholinesterase Inhibitors : Beneficial Effects on Comorbidities in Patients With Alzheimer’s Disease. / Kaushik, Vinod; Smith, Sarah Toombs; Mikobi, Emmanuel; Raji, Mukaila.

In: American Journal of Alzheimer's Disease and other Dementias, Vol. 33, No. 2, 01.03.2018, p. 73-85.

Research output: Contribution to journalReview article

@article{780052d916174d85998ebcc9a78ac105,
title = "Acetylcholinesterase Inhibitors: Beneficial Effects on Comorbidities in Patients With Alzheimer’s Disease",
abstract = "Elderly patients with Alzheimer’s disease (AD) and other dementias are at high risk of polypharmacy and excessive polypharmacy for common coexisting medical conditions. Polypharmacy increases the risk of drug–drug and drug–disease interactions in these patients who may not be able to communicate early symptoms of adverse drug events. Three acetylcholinesterase inhibitors (ACHEIs) have been approved for AD: donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne). They are also used off-label for other causes of dementia such as Lewy body and vascular dementia. We here report evidence from the literature that ACHEI treatment, prescribed for cognitive impairment, can reduce the load of medications in patients with AD by also addressing cardiovascular, gastrointestinal, and other comorbidities. Using one drug to address multiple symptoms can reduce costs and improve medication compliance.",
keywords = "acetylcholinesterase inhibitors, Alzheimer’s disease, comorbidities, off-label use, polypharmacy",
author = "Vinod Kaushik and Smith, {Sarah Toombs} and Emmanuel Mikobi and Mukaila Raji",
year = "2018",
month = "3",
day = "1",
doi = "10.1177/1533317517734352",
language = "English (US)",
volume = "33",
pages = "73--85",
journal = "American Journal of Alzheimer's Disease and other Dementias",
issn = "1533-3175",
publisher = "SAGE Publications Inc.",
number = "2",

}

TY - JOUR

T1 - Acetylcholinesterase Inhibitors

T2 - American Journal of Alzheimer's Disease and other Dementias

AU - Kaushik, Vinod

AU - Smith, Sarah Toombs

AU - Mikobi, Emmanuel

AU - Raji, Mukaila

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Elderly patients with Alzheimer’s disease (AD) and other dementias are at high risk of polypharmacy and excessive polypharmacy for common coexisting medical conditions. Polypharmacy increases the risk of drug–drug and drug–disease interactions in these patients who may not be able to communicate early symptoms of adverse drug events. Three acetylcholinesterase inhibitors (ACHEIs) have been approved for AD: donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne). They are also used off-label for other causes of dementia such as Lewy body and vascular dementia. We here report evidence from the literature that ACHEI treatment, prescribed for cognitive impairment, can reduce the load of medications in patients with AD by also addressing cardiovascular, gastrointestinal, and other comorbidities. Using one drug to address multiple symptoms can reduce costs and improve medication compliance.

AB - Elderly patients with Alzheimer’s disease (AD) and other dementias are at high risk of polypharmacy and excessive polypharmacy for common coexisting medical conditions. Polypharmacy increases the risk of drug–drug and drug–disease interactions in these patients who may not be able to communicate early symptoms of adverse drug events. Three acetylcholinesterase inhibitors (ACHEIs) have been approved for AD: donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne). They are also used off-label for other causes of dementia such as Lewy body and vascular dementia. We here report evidence from the literature that ACHEI treatment, prescribed for cognitive impairment, can reduce the load of medications in patients with AD by also addressing cardiovascular, gastrointestinal, and other comorbidities. Using one drug to address multiple symptoms can reduce costs and improve medication compliance.

KW - acetylcholinesterase inhibitors

KW - Alzheimer’s disease

KW - comorbidities

KW - off-label use

KW - polypharmacy

UR - http://www.scopus.com/inward/record.url?scp=85040908155&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040908155&partnerID=8YFLogxK

U2 - 10.1177/1533317517734352

DO - 10.1177/1533317517734352

M3 - Review article

VL - 33

SP - 73

EP - 85

JO - American Journal of Alzheimer's Disease and other Dementias

JF - American Journal of Alzheimer's Disease and other Dementias

SN - 1533-3175

IS - 2

ER -